Alaunos Therapeutics
TCRT
96 hedge funds and large institutions have $255M invested in Alaunos Therapeutics in 2014 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 4 closing their positions.
450% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 4
84% more call options, than puts
Call options by funds: $6.25M | Put options by funds: $3.4M
23% more funds holding
Funds holding: 78 → 96 (+18)
6% more capital invested
Capital invested by funds: $241M → $255M (+$14.3M)
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$3.69M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$3.23M |
| 3 |
SGAM
Smith Group Asset Management
Dallas,
Texas
|
+$682K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$574K |
| 5 |
Morgan Stanley
New York
|
+$539K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$4.63M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.33M |
| 3 |
Barclays
London,
United Kingdom
|
-$1.61M |
| 4 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
-$1.32M |
| 5 |
U
UBS
Zurich,
Switzerland
|
-$595K |
TCRT Hedge Fund Activity: Q1 2014 in Review
96 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2014, worth a combined $255M — up 5.9% from $241M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new TCRT positions and 4 closed out — a net gain of 18 holders — while 25 added to existing stakes and 24 trimmed.
The largest buyer was State Street, adding an estimated $3.69M. The largest seller was Jennison Associates, cutting an estimated $4.63M.
- 96 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2014, up from 78 in Q4 2013.
- Funds reported $255M of Alaunos Therapeutics stock for Q1 2014, up 5.9% quarter-over-quarter.
- 22 funds opened new Alaunos Therapeutics positions in Q1 2014 and 4 closed out, a net change of +18 holders.
- The largest Alaunos Therapeutics buyer in Q1 2014 was State Street, an estimated $3.69M added.
- The largest Alaunos Therapeutics seller in Q1 2014 was Jennison Associates, an estimated $4.63M sold.
Based on aggregated 13F filings for Q1 2014.